CNS Pharmaceuticals Inc - רווח נקי למניה (EPS TTM) CNSP

לוגו של חברה ציבורית CNS Pharma (CNSP)

CNS Pharmaceuticals is developing breakthrough treatments to overcome CNS barriers for the treatment of brain tumors. However, the lack of profitability and a heavy reliance on a single Phase 2 trial create significant risks. A competitive advantage is provided by the molecule's high permeability, which is confirmed by the EPS YoY TTM chart. The value of 68.40 serves as the final mark for this metric.

CNSP CNS Pharmaceuticals Inc: רווח למניה בשנים עשר החודשים האחרונים בטווח 11.02.2024 - 18.11.2026

CNSP (CNS Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- פרטי שווי השוק של המנפיק:
ניתוח ראשוני של החברה:CNSP (CNS Pharma)
מוצר המיוצר על ידי cnspharma.com

A fundamental valuation of CNS Pharmaceuticals (CNSP) requires an analysis of actual earnings per share dynamics. This metric measures the percentage change in trailing twelve-month (TTM) income, revealing the sustainability of the business's profitability trend. By analyzing the annual EPS TTM growth rate, an investor can discern the pace of net income capitalization. For a biotech firm focused on single tests for brain cancer, the volatility of this line reflects the risks associated with preclinical expenditures. Sharp fluctuations in this indicator signal the critical impact of research and development costs.